November 7, 2017

Syndax to Present at the SITC 32nd Annual Scientific Meeting

WALTHAM, Mass., Nov. 7, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced five presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting being held November 8-12, 2017 in National Harbor, Maryland.

Presentation Details

Syndax-Sponsored Oral Presentation

Title: ENCORE-601: Phase 1b/2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
Presenter: Leena Gandhi, MD, PhD
Abstract Number: O19
Abstract Category: Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)
Session: 207: Clinical Trials: Novel Combinations
Location: Maryland Ballroom A
Date and Time: Saturday, November 11, 2017; 3:45-4:00 pm

Syndax-Sponsored Poster Presentations

Title: Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat (ENT) and pembrolizumab (PEMBRO)
First Author: Melissa L. Johnson, MD
Abstract Number: P72
Abstract Category: Biomarkers and Immune Monitoring
Location: Prince George's Exhibition Hall DE
Date and Time: Saturday, November 11, 2017; 12:30-2:00 pm and 6:30-8:00 pm

Title: First in human, single ascending dose study in healthy volunteers of SNDX-6352, a humanized IgG4 monoclonal antibody targeting colony stimulating factor-1 receptor (CSF-1R)
First Author: Renger G. Tiessen, MD
Abstract Number: P505
Abstract Category: Various
Location: Prince George's Exhibition Hall DE
Date and Time: Friday, November 10, 2017; 12:30-2:00 pm and 6:30-8:00 pm

Collaborator-Sponsored Poster Presentations

Title: Epigenetic reprogramming of the tumor microenvironment increases tumor sensitivity to multivalent immunotherapy combinations with an IL-15 superagonist plus vaccine or immune checkpoint blockade
First Author: Kristin C. Hicks, PhD
Abstract Number: P269
Abstract Category: Combination Therapy (IO/IO, IO/Standard of Care, IO/Other)
Location: Prince George's Exhibition Hall DE
Date and Time: Friday, November 10, 2017; 12:30-2:00 pm and 6:30-8:00 pm

Title: Epigenetic modulation promotes tumor suppression and improves survival when combined with checkpoint inhibition in murine models of breast cancer
First Author: Evanthia Roussos Torres, MD, PhD
Abstract Number: P355
Abstract Category: Immune Modulation, Cytokines, and Antibodies
Location: Prince George's Exhibition Hall DE
Date and Time: Friday, November 10, 2017; 12:30-2:00 pm and 6:30-8:00 pm

The posters will be on display starting at 12:30 PM ET on Friday, November 10 and will remain accessible through 8:00 PM

ET on Saturday, November 11. All accepted abstracts will be available via the *Journal for ImmunoTherapy of Cancer* (JITC), SITC's global, open access, peer-reviewed journal.

About Syndax Pharmaceuticals, Inc.

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial in combination with exemestane for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, entinostat is also being evaluated in combination with approved PD-1 antagonists. Ongoing Phase 1b/2 clinical trials combine entinostat with KEYTRUDA from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with TECENTRIQ® from Genentech, Inc. for triple negative breast cancer; and with BAVENCIO® from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second clinical stage product candidate, SNDX-6352, is a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor and may also block the function of immune suppressive cells in the tumor microenvironment. SNDX-6352 is being evaluated in a Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.

Syndax's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and the potential use of our product candidates to treat various cancer indications. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Investor Contact

Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546

SNDX-G